Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography

Arturo Chiti, Roberto Agresti, Lorenzo S. Maffioli, Gorana Tomasic, Giordano Savelli, Flavio Crippa, Silvana Pilotti, Marco Greco, Emilio Bombardieri

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We evaluated the clinical usefulness of single-photon emission tomography (SPET) with technetium-99m sestamibi and indium-111 pentetreotide in breast cancer staging. Fifteen patients with clinical and/or mammographic findings suggesting T1-2N0-1 breast cancer were studied. SPET images were acquired 20 min after 99mTc-sestamibi injection and 4 and 24 h after 111In-pentetreotide injection. Patients underwent surgery the day after the later 111In-pentetreotide acquisition. Pathological examination showed 16 tumours in the 15 patients, with one bilateral carcinoma. The mean tumour diameter was 18.7 mm. Metastatic axillary involvement was found in 6/16 tumours, with a mean of five metastatic nodes per axilla. Both tracers correctly identified 15/16 primary tumours and five of the six cases of metastatic axillary node involvement. No difference between the tracers was observed in breast cancer staging. 99mTc-sestamibi seems to be the better tracer in terms of physical characteristics, execution time and cost-effectiveness. Our data suggest the future possibility of using nuclear medicine imaging to avoid axillary dissection in patients with T1 breast cancer.

Original languageEnglish
Pages (from-to)192-196
Number of pages5
JournalEuropean Journal Of Nuclear Medicine
Volume24
Issue number2
DOIs
Publication statusPublished - 1997

Fingerprint

Technetium Tc 99m Sestamibi
Neoplasm Staging
Photons
Tomography
Breast Neoplasms
Neoplasms
Injections
Axilla
Nuclear Medicine
Ambulatory Surgical Procedures
Cost-Benefit Analysis
Dissection
Carcinoma
pentetreotide

Keywords

  • Axillary lymph nodes
  • Breast cancer
  • Indium-111 pentetreotide
  • Technetium-99m sestamibi

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography. / Chiti, Arturo; Agresti, Roberto; Maffioli, Lorenzo S.; Tomasic, Gorana; Savelli, Giordano; Crippa, Flavio; Pilotti, Silvana; Greco, Marco; Bombardieri, Emilio.

In: European Journal Of Nuclear Medicine, Vol. 24, No. 2, 1997, p. 192-196.

Research output: Contribution to journalArticle

Chiti, Arturo ; Agresti, Roberto ; Maffioli, Lorenzo S. ; Tomasic, Gorana ; Savelli, Giordano ; Crippa, Flavio ; Pilotti, Silvana ; Greco, Marco ; Bombardieri, Emilio. / Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography. In: European Journal Of Nuclear Medicine. 1997 ; Vol. 24, No. 2. pp. 192-196.
@article{06223f1448ec4e559c49f3073d11ac0f,
title = "Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography",
abstract = "We evaluated the clinical usefulness of single-photon emission tomography (SPET) with technetium-99m sestamibi and indium-111 pentetreotide in breast cancer staging. Fifteen patients with clinical and/or mammographic findings suggesting T1-2N0-1 breast cancer were studied. SPET images were acquired 20 min after 99mTc-sestamibi injection and 4 and 24 h after 111In-pentetreotide injection. Patients underwent surgery the day after the later 111In-pentetreotide acquisition. Pathological examination showed 16 tumours in the 15 patients, with one bilateral carcinoma. The mean tumour diameter was 18.7 mm. Metastatic axillary involvement was found in 6/16 tumours, with a mean of five metastatic nodes per axilla. Both tracers correctly identified 15/16 primary tumours and five of the six cases of metastatic axillary node involvement. No difference between the tracers was observed in breast cancer staging. 99mTc-sestamibi seems to be the better tracer in terms of physical characteristics, execution time and cost-effectiveness. Our data suggest the future possibility of using nuclear medicine imaging to avoid axillary dissection in patients with T1 breast cancer.",
keywords = "Axillary lymph nodes, Breast cancer, Indium-111 pentetreotide, Technetium-99m sestamibi",
author = "Arturo Chiti and Roberto Agresti and Maffioli, {Lorenzo S.} and Gorana Tomasic and Giordano Savelli and Flavio Crippa and Silvana Pilotti and Marco Greco and Emilio Bombardieri",
year = "1997",
doi = "10.1007/BF02439552",
language = "English",
volume = "24",
pages = "192--196",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "2",

}

TY - JOUR

T1 - Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography

AU - Chiti, Arturo

AU - Agresti, Roberto

AU - Maffioli, Lorenzo S.

AU - Tomasic, Gorana

AU - Savelli, Giordano

AU - Crippa, Flavio

AU - Pilotti, Silvana

AU - Greco, Marco

AU - Bombardieri, Emilio

PY - 1997

Y1 - 1997

N2 - We evaluated the clinical usefulness of single-photon emission tomography (SPET) with technetium-99m sestamibi and indium-111 pentetreotide in breast cancer staging. Fifteen patients with clinical and/or mammographic findings suggesting T1-2N0-1 breast cancer were studied. SPET images were acquired 20 min after 99mTc-sestamibi injection and 4 and 24 h after 111In-pentetreotide injection. Patients underwent surgery the day after the later 111In-pentetreotide acquisition. Pathological examination showed 16 tumours in the 15 patients, with one bilateral carcinoma. The mean tumour diameter was 18.7 mm. Metastatic axillary involvement was found in 6/16 tumours, with a mean of five metastatic nodes per axilla. Both tracers correctly identified 15/16 primary tumours and five of the six cases of metastatic axillary node involvement. No difference between the tracers was observed in breast cancer staging. 99mTc-sestamibi seems to be the better tracer in terms of physical characteristics, execution time and cost-effectiveness. Our data suggest the future possibility of using nuclear medicine imaging to avoid axillary dissection in patients with T1 breast cancer.

AB - We evaluated the clinical usefulness of single-photon emission tomography (SPET) with technetium-99m sestamibi and indium-111 pentetreotide in breast cancer staging. Fifteen patients with clinical and/or mammographic findings suggesting T1-2N0-1 breast cancer were studied. SPET images were acquired 20 min after 99mTc-sestamibi injection and 4 and 24 h after 111In-pentetreotide injection. Patients underwent surgery the day after the later 111In-pentetreotide acquisition. Pathological examination showed 16 tumours in the 15 patients, with one bilateral carcinoma. The mean tumour diameter was 18.7 mm. Metastatic axillary involvement was found in 6/16 tumours, with a mean of five metastatic nodes per axilla. Both tracers correctly identified 15/16 primary tumours and five of the six cases of metastatic axillary node involvement. No difference between the tracers was observed in breast cancer staging. 99mTc-sestamibi seems to be the better tracer in terms of physical characteristics, execution time and cost-effectiveness. Our data suggest the future possibility of using nuclear medicine imaging to avoid axillary dissection in patients with T1 breast cancer.

KW - Axillary lymph nodes

KW - Breast cancer

KW - Indium-111 pentetreotide

KW - Technetium-99m sestamibi

UR - http://www.scopus.com/inward/record.url?scp=0030999787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030999787&partnerID=8YFLogxK

U2 - 10.1007/BF02439552

DO - 10.1007/BF02439552

M3 - Article

VL - 24

SP - 192

EP - 196

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 2

ER -